Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Related Posts
Ali B, Chauhan A, Kumar M, Kumar P, Carolus H, Lobo Romero C, Vergauwen R, Singh A, Banerjee A, Prakash A, Rudramurthy SM, Van Dijck[...]
Brown CO, Pham PC, Shah A, Dukkipati R, Shen J, Dai T, Raff EA, Kalantar-Zadeh K. Population health strategies for health equity in chronic kidney[...]
Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]